Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
National MS Society: Research Grants
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
A New Colour Reaction on Copper and Certain Carbonyl Compounds
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Pregnancy and multiple sclerosis.
Episode 12 with Professor Gavin Giovannoni on the potential for finding a cure for MS.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis.
MS Research Roundup: An Introduction
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Delayed visual evoked response in optic neuritis.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.

Pages